Enhancement of Scaffold In Vivo Biodegradability for Bone Regeneration Using P28 Peptide Formulations
-
Published:2023-06-13
Issue:6
Volume:16
Page:876
-
ISSN:1424-8247
-
Container-title:Pharmaceuticals
-
language:en
-
Short-container-title:Pharmaceuticals
Author:
Azaman Farah Alwani12ORCID, Brennan Fournet Margaret E.1ORCID, Sheikh Ab Hamid Suzina2, Zawawi Muhamad Syahrul Fitri2, da Silva Junior Valdemiro Amaro3, Devine Declan M.1ORCID
Affiliation:
1. PRISM Research Institute, Technological University of the Shannon (TUS), N37 HD68 Athlone, Ireland 2. Tissue Bank, School of Medical Sciences, Health Campus, Universiti Sains Malaysia (USM), 16150 Kota Bharu, Malaysia 3. Departamento de Medicina Veterinária, Universidade Federal Rural de Pernambuco, Recife 52171-900, Brazil
Abstract
The field of bone tissue engineering has shown a great variety of bone graft substitute materials under development to date, with the aim to reconstruct new bone tissue while maintaining characteristics close to the native bone. Currently, insufficient scaffold degradation remains the critical limitation for the success of tailoring the bone formation turnover rate. This study examines novel scaffold formulations to improve the degradation rate in vivo, utilising chitosan (CS), hydroxyapatite (HAp) and fluorapatite (FAp) at different ratios. Previously, the P28 peptide was reported to present similar, if not better performance in new bone production to its native protein, bone morphogenetic protein-2 (BMP-2), in promoting osteogenesis in vivo. Therefore, various P28 concentrations were incorporated into the CS/HAp/FAp scaffolds for implantation in vivo. H&E staining shows minimal scaffold traces in most of the defects induced after eight weeks, showing the enhanced biodegradability of the scaffolds in vivo. The HE stain highlighted the thickened periosteum indicating a new bone formation in the scaffolds, where CS/HAp/FAp/P28 75 µg and CS/HAp/FAp/P28 150 µg showed the cortical and trabecular thickening. CS/HAp/FAp 1:1 P28 150 µg scaffolds showed a higher intensity of calcein green label with the absence of xylenol orange label, which indicates that mineralisation and remodelling was not ongoing four days prior to sacrifice. Conversely, double labelling was observed in the CS/HAp/FAp 1:1 P28 25 µg and CS/HAp/FAp/P28 75 µg, which indicates continued mineralisation at days ten and four prior to sacrifice. Based on the HE and fluorochrome label, CS/HAp/FAp 1:1 with P28 peptides presented a consistent positive osteoinduction following the implantation in the femoral condyle defects. These results show the ability of this tailored formulation to improve the scaffold degradation for bone regeneration and present a cost-effective alternative to BMP-2.
Subject
Drug Discovery,Pharmaceutical Science,Molecular Medicine
Reference59 articles.
1. Kaliva, M., Georgopoulou, A., Dragatogiannis, D.A., Charitidis, C.A., Chatzinikolaidou, M., and Vamvakaki, M. (2020). Biodegradable Chitosan-Graft-Poly(L-Lactide) Copolymers for Bone Tissue Engineering. Polymers, 12. 2. Chitosan Grafted/Cross-Linked with Biodegradable Polymers: A Review;Balea;Int. J. Biol. Macromol.,2021 3. Dorati, R., DeTrizio, A., Modena, T., Conti, B., Benazzo, F., Gastaldi, G., and Genta, I. (2017). Biodegradable Scaffolds for Bone Regeneration Combined with Drug-Delivery Systems in Osteomyelitis Therapy. Pharmaceuticals, 10. 4. In Vivo Study of Conductive 3D Printed PCL/MWCNTs Scaffolds with Electrical Stimulation for Bone Tissue Engineering;Huang;Bio-Des. Manuf.,2021 5. Devine, D.M. (2019). Polymer-Based Additive Manufaturing: Biomedical Application, Springer.
Cited by
1 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献
|
|